注册 English

4,5,6,7-Tetrahydro-[1,2,3]triazolo[1,5-a]pyrazine as a new scaffold for heat shock protein 90 inhibitors

Meng-Yi Xu ,  Ni-Na Xue ,  Di Liu ,  Yu-Mei Zhou ,  Wei Li ,  Yong-Qiang Li ,  Xiao-Guang Chen ,  Xiao-Ming Yu

downloadPDF
Citation:  Meng-Yi Xu, Ni-Na Xue, Di Liu, Yu-Mei Zhou, Wei Li, Yong-Qiang Li, Xiao-Guang Chen, Xiao-Ming Yu. 4,5,6,7-Tetrahydro-[1,2,3]triazolo[1,5-a]pyrazine as a new scaffold for heat shock protein 90 inhibitors[J]. Chinese Chemical Letters, 2016, 27(01): 11-15. doi: 10.1016/j.cclet.2015.09.024 shu

4,5,6,7-Tetrahydro-[1,2,3]triazolo[1,5-a]pyrazine as a new scaffold for heat shock protein 90 inhibitors

  • 1.

    Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

    • 通讯作者: Xiao-Guang Chen,
    Xiao-Ming Yu,
  • 基金项目:

    This project is financially supported by the National Natural Science Foundation of China(No. 21272279). (No. 21272279)

摘要: Heat shock protein 90(hsp90) is a promising anticancer drug target. A library of 2,4-dihydroxyphenyl(resorcinol) substituted 4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyrazine compounds that target this protein were designed and prepared based on our earlier study. The compounds were tested in five cancer cell lines and seven of them showed notable anticancer activity(IC50 2-10μmol/L). The active subset compounds were further subjected to a polarized fluorescent assay and exhibited high binding affinity toward purified hsp90(IC50 60-100 nmol/L). These results indicated that the tetrahydrotriazolopyrazine motif of the molecules may represent a novel scaffold for the development of hsp90 inhibitors.

English

  • 

    1. [1] P. Csermely, T. Schnaider, C. Soti, Z. Prohászka, The 90-kDa molecular chaperone family:structure, function and clinical applications, Pharmacol. Ther. 79(1998) 129-168.[1] P. Csermely, T. Schnaider, C. Soti, Z. Prohászka, The 90-kDa molecular chaperone family:structure, function and clinical applications, Pharmacol. Ther. 79(1998) 129-168.

    2. [2](a) R. Garcia-Carbonero, A. Carnero, L. Paz-Ares, Inhibition of HSP90 molecular chaperones:moving into the clinic, Lancet Oncol. 14(2013) e358-e369;(b) H. Yamaki, M. Nakajima, K.W. Shimotohno, N. Tanaka, Molecular basis for the actions of Hsp90 inhibitors and cancer therapy, J. Antibiotics 64(2011) 635-644.[2](a) R. Garcia-Carbonero, A. Carnero, L. Paz-Ares, Inhibition of HSP90 molecular chaperones:moving into the clinic, Lancet Oncol. 14(2013) e358-e369;(b) H. Yamaki, M. Nakajima, K.W. Shimotohno, N. Tanaka, Molecular basis for the actions of Hsp90 inhibitors and cancer therapy, J. Antibiotics 64(2011) 635-644.

    3. [3](a) L. Whitesell, E.G. Mimnaugh, B. De Costa, C.E. Myers, L.M. Neckers, Inhibition of heat shock protein HSP90-pp6Ov-src heteroprotein complex formation by benzoquinone ansamycins:essential role for stress proteins in oncogenic transformation, Proc. Natl. Acad. Sci. U.S.A. 91(1994) 8324-8328;(b) T.W. Schulte, W.G. An, L.M. Neckers, Geldanamycin-induced destabilization of Raf-1 involves the proteasome, Biochem. Biophys. Res. Commun. 239(1997) 655-659.[3](a) L. Whitesell, E.G. Mimnaugh, B. De Costa, C.E. Myers, L.M. Neckers, Inhibition of heat shock protein HSP90-pp6Ov-src heteroprotein complex formation by benzoquinone ansamycins:essential role for stress proteins in oncogenic transformation, Proc. Natl. Acad. Sci. U.S.A. 91(1994) 8324-8328;(b) T.W. Schulte, W.G. An, L.M. Neckers, Geldanamycin-induced destabilization of Raf-1 involves the proteasome, Biochem. Biophys. Res. Commun. 239(1997) 655-659.

    4. [4](a) K. Jhaveri, T. Taldone, S. Modi, G. Chiosis, Advances in the clinical development of heat shock protein 90(Hsp90) inhibitors in cancers, Biochim. Biophys. Acta 1823(2012) 742-755;(b) F. Zagouri, T.N. Sergentanis, D. Chrysikos, et al., Hsp90 inhibitors in breast cancer:a systematic review, The Breast 22(2013) 569-578;(c) R. Bhat, S.R. Tummalapalli, D.P. Rotella, Progress in the discovery and development of heat shock protein 90(Hsp90) inhibitors, J. Med. Chem. 57(2014) 8718-8728;(d) L. Neckers, J.B. Trepel, Stressing the development of small molecules targeting HSP90, Clin. Cancer Res. 20(2014) 275-277;(e) K. Jhaveri, S.O. Ochiana, M.P.S. Dunphy, et al., Heat shock protein 90 inhibitors in the treatment of cancer:current status and future directions, Expert Opin. Investig. Drugs 23(2014) 611-628.[4](a) K. Jhaveri, T. Taldone, S. Modi, G. Chiosis, Advances in the clinical development of heat shock protein 90(Hsp90) inhibitors in cancers, Biochim. Biophys. Acta 1823(2012) 742-755;(b) F. Zagouri, T.N. Sergentanis, D. Chrysikos, et al., Hsp90 inhibitors in breast cancer:a systematic review, The Breast 22(2013) 569-578;(c) R. Bhat, S.R. Tummalapalli, D.P. Rotella, Progress in the discovery and development of heat shock protein 90(Hsp90) inhibitors, J. Med. Chem. 57(2014) 8718-8728;(d) L. Neckers, J.B. Trepel, Stressing the development of small molecules targeting HSP90, Clin. Cancer Res. 20(2014) 275-277;(e) K. Jhaveri, S.O. Ochiana, M.P.S. Dunphy, et al., Heat shock protein 90 inhibitors in the treatment of cancer:current status and future directions, Expert Opin. Investig. Drugs 23(2014) 611-628.

    5. [5](a) J.-M. Jia, F. Liu, X.-L. Xu, et al., Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold, Bioorg. Med. Chem. Lett. 24(2014) 1557-1561;(b) J. Ren, J. Li, Y. Wang, et al., Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization, Bioorg. Med. Chem. Lett. 24(2014) 2525-2529;(c) M. Taddei, S. Ferrini, L. Giannotti, et al., Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold, J. Med. Chem. 57(2014) 2258-2274.[5](a) J.-M. Jia, F. Liu, X.-L. Xu, et al., Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold, Bioorg. Med. Chem. Lett. 24(2014) 1557-1561;(b) J. Ren, J. Li, Y. Wang, et al., Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization, Bioorg. Med. Chem. Lett. 24(2014) 2525-2529;(c) M. Taddei, S. Ferrini, L. Giannotti, et al., Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold, J. Med. Chem. 57(2014) 2258-2274.

    6. [6] P.A. Brough, W. Aherne, X. Barril, et al., 4,5-Diarylisoxazole hsp90 chaperone inhibitors:potential therapeutic agents for the treatment of cancer, J. Med. Chem. 51(2008) 196-218.[6] P.A. Brough, W. Aherne, X. Barril, et al., 4,5-Diarylisoxazole hsp90 chaperone inhibitors:potential therapeutic agents for the treatment of cancer, J. Med. Chem. 51(2008) 196-218.

    7. [7] D.A. Proia, R.C. Bates, Ganetespib and hsp90:translating preclinical hypotheses into clinical promise, Cancer Res. 74(2014) 1294-1300.[7] D.A. Proia, R.C. Bates, Ganetespib and hsp90:translating preclinical hypotheses into clinical promise, Cancer Res. 74(2014) 1294-1300.

    8. [8] A.J. Woodhead, H. Angove, M.G. Carr, et al., Discovery of(2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone(AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design, J. Med. Chem. 53(2010) 5956-5969.[8] A.J. Woodhead, H. Angove, M.G. Carr, et al., Discovery of(2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone(AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design, J. Med. Chem. 53(2010) 5956-5969.

    9. [9] C. Lu, D. Liu, J. Jin, et al., Inhibition of gastric tumor growth by a novel Hsp90 inhibitor, Biochem. Pharmacol. 85(2013) 1246-1256.[9] C. Lu, D. Liu, J. Jin, et al., Inhibition of gastric tumor growth by a novel Hsp90 inhibitor, Biochem. Pharmacol. 85(2013) 1246-1256.

    10. [10] R. Severin, J. Reimer, S. Doye, One-pot procedure for the synthesis of unsymmetrical diarylalkynes, J. Org. Chem. 75(2010) 3518-3521.[10] R. Severin, J. Reimer, S. Doye, One-pot procedure for the synthesis of unsymmetrical diarylalkynes, J. Org. Chem. 75(2010) 3518-3521.

  • 加载中
WeChat 扫一扫看文章
计量
  • PDF下载量:  0
  • 文章访问数:  1472
  • HTML全文浏览量:  39
文章相关
  • 发布日期:  2015-11-12
  • 收稿日期:  2015-07-02
  • 网络出版日期:  2015-08-18
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章

All Rights Reserved by the Chinese Chemical Society   中国化学会 版权所有 京ICP备05002797号

本系统由北京仁和汇智信息技术有限公司开发    技术支持: info@rhhz.net